Comprehensive study on ERG gene expression in normal karyotype acute myeloid leukemia: ERG expression is of limited prognostic value, whereas the accumulation of adverse prognostic...

por Weber, S, Haferlach, T, Haferlach, C, Kern, W
Publicado 2016

Gene expression profiling for the diagnosis of acute leukaemia

por Haferlach, T, Kohlmann, A, Bacher, U, Schnittger, S, Haferlach, C, Kern, W
Publicado 2007

The new provisional WHO entity ‘RUNX1 mutated AML' shows specific genetics but no prognostic influence of dysplasia

por Haferlach, T, Stengel, A, Eckstein, S, Perglerová, K, Alpermann, T, Kern, W, Haferlach, C, Meggendorfer, M
Publicado 2016

Molecular analysis of RAS-RAF tyrosine-kinase signaling pathway alterations in patients with plasma cell myeloma

por Grossmann, V, Bacher, U, Artusi, V, Kohlmann, A, Nadarajah, N, Kern, W, Schnittger, S, Haferlach, T, Haferlach, C
Publicado 2012

Expression of CEBPA is reduced in RUNX1-mutated acute myeloid leukemia

por Grossmann, V, Bacher, U, Kohlmann, A, Butschalowski, K, Roller, A, Jeromin, S, Dicker, F, Kern, W, Schnittger, S, Haferlach, T, Haferlach, C
Publicado 2012

BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia

por Weber, S, Alpermann, T, Dicker, F, Jeromin, S, Nadarajah, N, Eder, C, Fasan, A, Kohlmann, A, Meggendorfer, M, Haferlach, C, Kern, W, Haferlach, T, Schnittger, S
Publicado 2014

European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms

por Rack, K. A., van den Berg, E., Haferlach, C., Beverloo, H. B., Costa, D., Espinet, B., Foot, N., Jeffries, S., Martin, K., O’Connor, S., Schoumans, J., Talley, P., Telford, N., Stioui, S., Zemanova, Z., Hastings, R. J.
Publicado 2019

European recommendations and quality assurance for cytogenomic analysis of haematological neoplasms: reponse to the comments from the Francophone Group of Hematological Cytogenetic...

por Rack, K. A., van den Berg, E., Haferlach, C., Beverloo, H. B., Costa, D., Espinet, B., Foot, N., Jeffries, S., Martin, K., O’Connor, S., Schoumans, J., Talley, P., Telford, N., Stioui, S., Zemanova, Z., Hastings, R. J.
Publicado 2020

The molecular pathogenesis of the NUP98-HOXA9 fusion protein in acute myeloid leukemia

por Rio-Machin, A, Gómez-López, G, Muñoz, J, Garcia-Martinez, F, Maiques-Diaz, A, Alvarez, S, Salgado, R N, Shrestha, M, Torres-Ruiz, R, Haferlach, C, Larráyoz, M J, Calasanz, M J, Fitzgibbon, J, Cigudosa, J C
Publicado 2017

P52 RISK STRATIFICATION COMBINING SKY92 GENE EXPRESSION PROFILING AND TRADITIONAL FISH IN MULTIPLE MYELOMA: THE FIRST PROSPECTIVE EVIDENCE IN THE R2-ISS ERA

por Zhou, X., Hofmann, A., Vogt, C., Nerreter, S., Teufel, E., Stanojkovska, E., Truger, M., Engel, B., Xiao, X., Eisele, F., Weis, P., Barcic, A., Peter, J., Riedhammer, C., Steinhardt, M. J., Hornburger, H., Han, S., Haertle, L., Munawar, U., Mersi, J., Haferlach, C., Einsele, H., Kortüm, K. M., Rasche, L.
Publicado 2023

Landscape of genetic lesions in 944 patients with myelodysplastic syndromes

por Haferlach, T, Nagata, Y, Grossmann, V, Okuno, Y, Bacher, U, Nagae, G, Schnittger, S, Sanada, M, Kon, A, Alpermann, T, Yoshida, K, Roller, A, Nadarajah, N, Shiraishi, Y, Shiozawa, Y, Chiba, K, Tanaka, H, Koeffler, H P, Klein, H-U, Dugas, M, Aburatani, H, Kohlmann, A, Miyano, S, Haferlach, C, Kern, W, Ogawa, S
Publicado 2014

The role of the RAS pathway in iAMP21-ALL

por Ryan, S L, Matheson, E, Grossmann, V, Sinclair, P, Bashton, M, Schwab, C, Towers, W, Partington, M, Elliott, A, Minto, L, Richardson, S, Rahman, T, Keavney, B, Skinner, R, Bown, N, Haferlach, T, Vandenberghe, P, Haferlach, C, Santibanez-Koref, M, Moorman, A V, Kohlmann, A, Irving, J A E, Harrison, C J
Publicado 2016

Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment

por Gratwohl, A, Pfirrmann, M, Zander, A, Kröger, N, Beelen, D, Novotny, J, Nerl, C, Scheid, C, Spiekermann, K, Mayer, J, Sayer, H G, Falge, C, Bunjes, D, Döhner, H, Ganser, A, Schmidt-Wolf, I, Schwerdtfeger, R, Baurmann, H, Kuse, R, Schmitz, N, Wehmeier, A, Th Fischer, J, Ho, A D, Wilhelm, M, Goebeler, M-E, Lindemann, H W, Bormann, M, Hertenstein, B, Schlimok, G, Baerlocher, G M, Aul, C, Pfreundschuh, M, Fabian, M, Staib, P, Edinger, M, Schatz, M, Fauser, A, Arnold, R, Kindler, T, Wulf, G, Rosselet, A, Hellmann, A, Schäfer, E, Prümmer, O, Schenk, M, Hasford, J, Heimpel, H, Hossfeld, D K, Kolb, H-J, Büsche, G, Haferlach, C, Schnittger, S, Müller, M C, Reiter, A, Berger, U, Saußele, S, Hochhaus, A, Hehlmann, R
Publicado 2016

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

por Hehlmann, R, Lauseker, M, Saußele, S, Pfirrmann, M, Krause, S, Kolb, H J, Neubauer, A, Hossfeld, D K, Nerl, C, Gratwohl, A, Baerlocher, G M, Heim, D, Brümmendorf, T H, Fabarius, A, Haferlach, C, Schlegelberger, B, Müller, M C, Jeromin, S, Proetel, U, Kohlbrenner, K, Voskanyan, A, Rinaldetti, S, Seifarth, W, Spieß, B, Balleisen, L, Goebeler, M C, Hänel, M, Ho, A, Dengler, J, Falge, C, Kanz, L, Kremers, S, Burchert, A, Kneba, M, Stegelmann, F, Köhne, C A, Lindemann, H W, Waller, C F, Pfreundschuh, M, Spiekermann, K, Berdel, W E, Müller, L, Edinger, M, Mayer, J, Beelen, D W, Bentz, M, Link, H, Hertenstein, B, Fuchs, R, Wernli, M, Schlegel, F, Schlag, R, de Wit, M, Trümper, L, Hebart, H, Hahn, M, Thomalla, J, Scheid, C, Schafhausen, P, Verbeek, W, Eckart, M J, Gassmann, W, Pezzutto, A, Schenk, M, Brossart, P, Geer, T, Bildat, S, Schäfer, E, Hochhaus, A, Hasford, J
Publicado 2017